13F Pro

CTSOCytosorbents Corp(CTSO)Stock Analysis

AI analysis on 2,800+ stocks →
Healthcare →Nasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 1175151CTSO stock profile & AI dashboard →

13F Pro Quality Score

19.5/100

Rank #2,691 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

32.5/100

Profitability

18.2/100

Balance Sheet

12.7/100

Earnings Quality

30.0/100

Free Cash Flow

13.0/100

Institutional Flow

33.7/100

Revenue Scale

8.7/100

Dilution Risk

20.7/100

CTSO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cytosorbents Corp (CTSO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CTSO at 19.5/100 on a 32-signal composite quality model, placing it at rank #2,691 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (8.7) and balance sheet strength (12.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cytosorbents Corp reports quarterly revenue of $8.9M, net income of $-5.1M, an operating margin of -34.3%. Top institutional holders of CTSO by reported 13-F value include AVENIR, VANGUARD CAPITAL MANAGEMENT, Skylands Capital,, based on the most recent SEC filings. CTSO trades on the Nasdaq exchange and files with the SEC under CIK 1175151. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTSO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cytosorbents Corp directly from SEC EDGAR.

✦

Fun facts about Cytosorbents Corp

Quirks, history, and lore behind CTSO — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. medical technology company · small-cap · listed on Nasdaq · headquartered in New Jersey.
  • 2
    The Numbers
    Annual revenue in the range of $30–40 million — not exactly a pharma titan — with most sales driven by a single flagship product used in hospital critical care settings.
  • 3
    The History
    Founded in the early 2000s, the company spun out of academic research into blood purification technology and spent years navigating FDA approval pathways before gaining commercial traction.
  • 4
    The Secret
    Its core technology works by adsorbing cytokines and inflammatory mediators directly from the bloodstream — essentially a tiny bouncer that yanks dangerous proteins out of circulation.
  • 5
    The Lore
    Its device gained significant attention during COVID-19 as hospitals explored treatments for the deadly cytokine storm that killed critically ill patients, sparking a wave of emergency use interest.
  • 6
    The Giveaway
    Its CytoSorb cartridge is approved in over 70 countries to filter the blood of sepsis and cardiac surgery patients — a company literally named after what its one device does.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$8.9M

Net Income

Q1 2026

$-5.1M

Free Cash Flow

Q1 2026

$-1.2M

Operating Margin

Q1 2026

-34.3%

Get alerted when CTSO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cytosorbents Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of CTSO

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CTSO on your watchlist

Track score changes the day Cytosorbents Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

META

Meta

13F Pro HomeView PricingFeatures

Is CTSO a good stock to buy?

13F Pro's AI-powered analysis of Cytosorbents Corp (CTSO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CTSO are available on the CTSO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CTSO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CTSO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cytosorbents Corp's investment landscape.